max）和血清炎性因子水平。結果 治療后，對照組、治療組的總有效率分別為86.00%、98.00%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組IPSS評分、QOL評分均顯著降低（P<0.05）；且治療組IPSS評分、QOL評分降低較多（P<0.05）。治療后，兩組RV、PV水平均顯著降低，Qmax水平顯著升高（P<0.05）；且治療組RV、PV水平顯著低于對照組，Qmax水平顯著高于對照組（P<0.05）。治療后，兩組患者IL-6、TNF-α水平均明顯降低（P<0.05）；且治療組IL-6、TNF-α水平降低較多（P<0.05）。結論 前列舒丸聯(lián)合甲磺酸多沙唑嗪片治療前列腺增生癥具有較好的臨床療效，可改善臨床癥狀，降低血清炎性因子水平，值得在臨床上推廣應用。;Objective To study the effect of Qianqianshu Pills combined with Doxazosin Mesylate Tablets in treatment of prostatic hyperplasia. Methods Patients (100 cases) with prostatic hyperplasia in First Affiliated Hospital of Zhengzhou University from July 2018 to July 2019 were randomly divided into control (50 cases) and treatment (50 cases) groups. Patients in the control group were po administered with Doxazosin Mesylate Tablets, 1 mg/time, once daily. Patients in the treatment group were po administered with Qianqianshu Pills on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the international prostate symptom score (IPSS) and quality of life score (QOL) scores, prostate volume (PV), bladder residual urine volume (RV), maximum urine flow rate (Qmax) and serum inflammatory factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.00% and 98.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, IPSS and QOL scores in two groups were significantly decreased (P < 0.05). And IPSS and QOL scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, RV and PV in two groups were significantly decreased, but Qmax in two groups were significantly increased (P < 0.05). And RV and PV in the treatment group were significantly lower than those in the control group, but Qmax in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of IL-6 and TNF-α in two groups were significantly decreased (P < 0.05). And the levels of IL-6 and TNF-α in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qianqianshu Pills combined with Doxazosin Mesylate Tablets has clinical curative effect in treatment of prostatic hyperplasia, can improve clinical symptoms and reduce the levels of serum inflammatory factors, which has a certain clinical application value."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2020年第35卷第2期 >2020,35(2):243-246. DOI:10.7501/j.issn.1674-5515.2020.02.010
上一篇 | 下一篇

前列舒丸聯(lián)合多沙唑嗪治療前列腺增生癥的臨床研究

Clinical study on Qianqianshu Pills combined with doxazosin in treatment of prostatic hyperplasia

發(fā)布日期：2020-03-07
  • 摘要
  • 圖/表
  • 訪問統(tǒng)計
  • PDF預覽
  • 參考文獻
  • 相似文獻
  • 引證文獻
  • 附件
    [關鍵詞]
    [摘要]
    目的 研究前列舒丸聯(lián)合甲磺酸多沙唑嗪片治療前列腺增生的臨床療效。方法 選取2018年7月-2019年7月來鄭州大學第一附屬醫(yī)院治療的100例前列腺增生癥患者，將所有患者隨機分為對照組和治療組，每組各50例。對照組患者口服甲磺酸多沙唑嗪片，1 mg/次，1次/d；治療組在對照組治療的基礎上口服前列舒丸，1粒/次，3次/d。兩組患者持續(xù)治療3個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者國際前列腺癥狀評分（IPSS）、生活質量（QOL）評分、前列腺體積（PV）、膀胱殘余尿量（RV）、最大尿流率（Qmax）和血清炎性因子水平。結果 治療后，對照組、治療組的總有效率分別為86.00%、98.00%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組IPSS評分、QOL評分均顯著降低（P<0.05）；且治療組IPSS評分、QOL評分降低較多（P<0.05）。治療后，兩組RV、PV水平均顯著降低，Qmax水平顯著升高（P<0.05）；且治療組RV、PV水平顯著低于對照組，Qmax水平顯著高于對照組（P<0.05）。治療后，兩組患者IL-6、TNF-α水平均明顯降低（P<0.05）；且治療組IL-6、TNF-α水平降低較多（P<0.05）。結論 前列舒丸聯(lián)合甲磺酸多沙唑嗪片治療前列腺增生癥具有較好的臨床療效，可改善臨床癥狀，降低血清炎性因子水平，值得在臨床上推廣應用。
    [Key word]
    [Abstract]
    Objective To study the effect of Qianqianshu Pills combined with Doxazosin Mesylate Tablets in treatment of prostatic hyperplasia. Methods Patients (100 cases) with prostatic hyperplasia in First Affiliated Hospital of Zhengzhou University from July 2018 to July 2019 were randomly divided into control (50 cases) and treatment (50 cases) groups. Patients in the control group were po administered with Doxazosin Mesylate Tablets, 1 mg/time, once daily. Patients in the treatment group were po administered with Qianqianshu Pills on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the international prostate symptom score (IPSS) and quality of life score (QOL) scores, prostate volume (PV), bladder residual urine volume (RV), maximum urine flow rate (Qmax) and serum inflammatory factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.00% and 98.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, IPSS and QOL scores in two groups were significantly decreased (P < 0.05). And IPSS and QOL scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, RV and PV in two groups were significantly decreased, but Qmax in two groups were significantly increased (P < 0.05). And RV and PV in the treatment group were significantly lower than those in the control group, but Qmax in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of IL-6 and TNF-α in two groups were significantly decreased (P < 0.05). And the levels of IL-6 and TNF-α in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qianqianshu Pills combined with Doxazosin Mesylate Tablets has clinical curative effect in treatment of prostatic hyperplasia, can improve clinical symptoms and reduce the levels of serum inflammatory factors, which has a certain clinical application value.
    [中圖分類號]
    R983
    [基金項目]
    河南省科技計劃項目（172102310021）